PHASE III STUDY OF PALBOCICLIB (PD-0332991) IN COMBINATION WITH ENDOCRINE THERAPY (EXEMESTANE OR FULVESTRANT) VERSUS CHEMOTHERAPY (CAPECITABINE) IN HORMONAL RECEPTOR (HR) POSITIVE/HER2 NEGATIVE METASTATIC BREAST CANCER (MBC) PATIENTS WITH RESISTANCE TO NON-STEROIDAL AROMATASE INHIBITORS: